SSRI DISCUSSION FORUM: Crestor needed revised label warning due to muscle and renal toxicity

"The release of Crestor, the newest of the statin drugs was associated almost immediately with a need for a revised package insert because of a rash of adverse drug reports of muscle and renal toxicity. What else could you expect from Astra-Zeneca's rosuvastatin, promoted as the most powerful of the powerful statin drugs already on the market?

Suddenly, increased numbers of rhabdomyolysis reports began to surface in Crestor users associated with secondary kidney damage and a more ominous threat of specific primary renal toxicity as well and the necessity to issue emergency warnings advising doctors to exercise special caution in the use of this drug with hypothyroidism, renal insufficiency, Asian sub-population groups and cyclosporine and gemfibrozil takers. Not a terribly auspicious welcome for Crestor, this new statin drug known for strength in a market already dominated by other powerful statins..."